TSE:BLU

BELLUS Health - BLU Stock Forecast, Price & News

C$10.64

+0.22 (+2.11%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: C$10.30
▼
C$10.67
50-Day Range: C$9.89
▼
C$11.11
52-Week Range: C$7.41
▼
C$16.24

Volume: 41,240 shs
Average Volume: 51,395 shs
Market Capitalization: C$1.34 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$20.00

About BELLUS Health (TSE:BLU) Stock

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

March 6, 2023 | msn.com

4 Biotech Stocks That Could Break Through the Market

March 1, 2023 | finance.yahoo.com

BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

March 22, 2023 | Upexi, Inc (Ad)

The Stock That Is Flying Under Wall St. Radar

With The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!

February 1, 2023 | markets.businessinsider.com

TSX Recovers After Mid-session Setback, Ends Just Marginally Down

January 20, 2023 | markets.businessinsider.com

TSX Rises 0.8%, Ends At 1-month High

December 20, 2022 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF) and BELLUS Health (BLU)

December 16, 2022 | markets.businessinsider.com

Canadian Shares Extending Losses As Growth Worries Weight On Sentiment

November 17, 2022 | finance.yahoo.com

BELLUS Health Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

March 22, 2023 | Upexi, Inc (Ad)

The Stock That Is Flying Under Wall St. Radar

With The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!

October 11, 2022 | seekingalpha.com

BLU BELLUS Health Inc.

September 7, 2022 | theglobeandmail.com

Closing Bell: Bellus Health Inc down on Friday (BLU)

August 14, 2022 | seekingalpha.com

BELLUS Health (BLU) Investor Presentation - Slideshow

August 10, 2022 | finance.yahoo.com

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

August 3, 2022 | finance.yahoo.com

Do Institutions Own BELLUS Health Inc. (TSE:BLU) Shares?

July 13, 2022 | finance.yahoo.com

BELLUS Health Shares Slide On Public Offering Of Shares In Canada And US

July 12, 2022 | finance.yahoo.com

BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program

July 12, 2022 | finance.yahoo.com

Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough

July 11, 2022 | finance.yahoo.com

Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?

June 7, 2022 | finance.yahoo.com

Are Medical Stocks Lagging Bellus Health (BLU) This Year?

June 1, 2022 | finance.yahoo.com

BELLUS Health to Participate in the Jefferies Healthcare Conference

May 30, 2022 | finance.yahoo.com

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

May 20, 2022 | fool.ca

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

May 2, 2022 | finance.yahoo.com

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

April 27, 2022 | benzinga.com

BELLUS Health to Participate in Multiple Upcoming...

February 23, 2022 | apnews.com

Bellus: Q4 Earnings Snapshot

January 25, 2022 | nasdaq.com

BELLUS Health Inc. Common Shares (BLU)

December 21, 2021 | finance.yahoo.com

Is BELLUS Health (TSE:BLU) In A Good Position To Invest In Growth?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Company Calendar

Today: 3/21/2023
Next Earnings (Estimated): 3/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:BLU
CUSIP: N/A
CIK: N/A
Web: www.bellushealth.com
Phone: +1-450-6804500
Fax: N/A
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$20.00
High Stock Price Forecast: C$24.00
Low Stock Price Forecast: C$16.00
Forecasted Upside/Downside: +88.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: C$-72,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -28.91%
Return on Assets: -16.72%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 16.96
Quick Ratio: 16.40

Sales & Book Value

Annual Sales: C$16,000.00
Price / Sales: 83,650.35
Cash Flow: C$2.28 per share
Price / Cash Flow: 4.67
Book Value: C$3.23 per share
Price / Book: 3.29

Miscellaneous

Outstanding Shares: 125,790,000
Free Float: N/A
Market Cap: C$1.34 billion
Optionable: Not Optionable
Beta: -0.51

Key Executives

Mr. Roberto Francesco Bellini (Age 43)
Pres, CEO & Director
Comp: $353.03k

Mr. Ramzi Benamar (Age 50)
Chief Financial Officer
Comp: $607.33k

Dr. Denis Garceau (Age 66)
Chief Scientific Officer
Comp: $431.87k

Mr. Tony Matzouranis (Age 50)
Sr. VP of Bus. Devel.
Comp: $272.89k

Dr. Catherine M. Bonuccelli M.D. (Age 65)
Chief Medical Officer
Comp: $703.77k

Dr. Andreas Orfanos FFPM (Age 64)
M.B.B.Ch, MBA, Chief Operating Officer

Mr. Daniel Matthews
Director of Investor Relations & Communications

Mr. Sebastien Roy (Age 47)
Corp. Sec.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

BLU Stock - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLU shares.
View BLU analyst ratings or view top-rated stocks.
What is BELLUS Health's stock price forecast for 2023?: 2 equities research analysts have issued 12-month price objectives for BELLUS Health's stock. Their BLU share price forecasts range from C$16.00 to C$24.00. On average, they expect the company's stock price to reach C$20.00 in the next year. This suggests a possible upside of 88.0% from the stock's current price.
View analysts price targets for BLU or view top-rated stocks among Wall Street analysts.
How have BLU shares performed in 2023?: BELLUS Health's stock was trading at C$11.08 at the beginning of 2023. Since then, BLU stock has decreased by 4.0% and is now trading at C$10.64.
View the best growth stocks for 2023 here.
When is BELLUS Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our BLU earnings forecast.

What other stocks do shareholders of BELLUS Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), Boeing (BA) and Walt Disney (DIS).
What is BELLUS Health's stock symbol?: BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."
How do I buy shares of BELLUS Health?: Shares of BLU stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is BELLUS Health's stock price today?: One share of BLU stock can currently be purchased for approximately C$10.64.
How much money does BELLUS Health make?: BELLUS Health (TSE:BLU) has a market capitalization of C$1.34 billion and generates C$16,000.00 in revenue each year. The company earns C$-72,600,000.00 in net income (profit) each year or C($0.96) on an earnings per share basis.
How can I contact BELLUS Health?: BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The official website for the company is www.bellushealth.com. The company can be reached via phone at +1-450-6804500.

This page (TSE:BLU) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial